

1653  
160

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on November 13, 2006

Patent Application  
Docket No. ARS-125  
Serial No. 10/570,121

*Frank C. Eisenschenk*

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ilya Chumakov, Oxana Guerassimenko  
Serial No. : 10/570,121  
Filed : February 28, 2006  
Conf. No. : 7412  
For : Novel UBP8rp Polypeptides and Their Use in the Treatment of Psoriasis

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Sir:

The above-referenced patent application was filed with unsigned Power of Attorney and Correspondence Address Indication Forms. Transmitted herewith are fully executed Power of Attorney forms by the inventors for the subject application.

A Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures of Missing Requirements was received from the Patent and Trademark Office, and a copy of that Notification is attached hereto. The Notification indicates that the subject application does not comply with the sequence requirements of 37 CFR §§1.821-1.825. Attached with this Transmittal Letter is a Submission of Sequence Listing Under 37 CFR §§1.821-1.825 providing the sequence listing in computer readable format.

The Commissioner is hereby authorized to charge any additional fees which may be required to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Telephone No.: (352) 375-8100

Facsimile No.: (352) 372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Enclosures: Executed Power of Attorney forms; Submission of Sequence Listing; Copy of Notification to Comply with Requirements




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/570,121	FIRST NAMED APPLICANT Ilya Chumakov	ATTY. DOCKET NO. ARS-125
---	--	-----------------------------

INTERNATIONAL APPLICATION NO. PCT/EP04/52000	
I.A. FILING DATE 09/02/2004	PRIORITY DATE 09/04/2003

23557  
 SALIWANCHIK LLOYD & SALIWANCHIK  
 A PROFESSIONAL ASSOCIATION  
 PO BOX 142950  
 GAINESVILLE, FL 32614-2950



CONFIRMATION NO. 7412  
 371 FORMALITIES LETTER  

 \*OC000000020768102\*

Date Mailed: 10/11/2006

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VIRGINIA L IRBY

---

Telephone: (571) 272-7633

---

PART 1 - ATTORNEY/APPLICANT COPY

---

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/570,121	PCT/EP04/52000	ARS-125

FORM PCT/DO/EO/922 (371 Formalities Notice)